Biogen has disclosed in a Wednesday Securities and Exchange Commission filing that it has been served a subpoena by the U.S. Department of Justice, which is seeking more information regarding the company’s overseas operations.
Tag Archive for: Tecfidera
The European Commission upheld exclusive marketing protection in Europe for Biogen’s multiple sclerosis therapy Tecfidera until February 3, 2025, staving off generic competition.
While the patent for Biogen’s drug has expired in the United States, it had scored a win in Europe in March.
Biogen is laying off an unspecified number of employees, according to a article published Monday by the Boston Business Journal.
Biogen Inc. (BIIB.O) Chief Executive Officer Christopher Viehbacher said on Wednesday he is banking on high-profile launches of Alzheimer’s disease treatment Leqembi and depression drug zuranolone, as well as deals, to help the company return to revenue growth.
The U.S. Supreme Court on Monday declined to hear Biogen Inc’s (BIIB.O) bid to win reinstatement of a patent on the company’s blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc. subsidiary (VTRS.O) Mylan Pharmaceuticals Inc.
The lawsuit accused Biogen of directing millions of dollars in kickbacks to doctors to prescribe its MS drugs Avonex, Tysabri and Tecfidera from 2009 to 2014, with kickbacks delivered in the form of “sham” consulting deals and speaker programs as well as lavish dinners and entertainment.
Biogen Inc. on Wednesday tried to assuage investor worries by laying out a plan for its Alzheimer’s disease drug being developed with Eisai Co. Ltd. and promising to draw lessons from the setbacks to its treatment Aduhelm.
